(Sharecast News) - Pharmaceuticals firm Merck reported a solid third quarter on Thursday, with revenue up 4% year-over-year to $16.7bn, driven by robust sales of its cancer drug Keytruda, although muted demand for the Gardasil HPV vaccine remained a challenge.
Adjusted earnings per share came in at $1.57, surpassing analysts' expectations...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE